

REMARKS

Reconsideration and allowance of this application are respectfully requested in light of the foregoing amendments and the following remarks.

Claim Status

Claims 1-8 were presented in the originally filed application. New claims 9-14 were added. Claims 2-3 and 8-14 are cancelled. Claims 1, 4, 5 and 7 are allowed. Claim 6 is pending. No new matter was added.

Allowed Claims

Applicant acknowledged the allowance of claims 1, 4, 5 and 7 and thanks the Examiner for those allowances.

§112 Rejection

Claim 14 stands rejected under 35 U.S.C. §112, first paragraph as failing to comply with the written restriction requirement. Applicant traverses.

Claim 14 has been cancelled so this rejection is no longer relevant.

Claim Objections

The Examiner has objected to claims 6, 11 and 14 under 37 CFR 1.75. Applicant traverses.

Claims 11 and 14 have each been cancelled, so the objection to these two claims is no longer relevant. As to claim 6, the Examiner objects that it is a substantial duplicate of claim 5. After conducting a brief interview with the Examiner concerning this objection, the Examiner stated that the Examiner will consider Applicants' argument that perindopril erbumine has been approved by the FDA for use in the treatment of hypertension, stable coronary artery disease and heart failure. Because of the FDA's approval, claim 6 is enabled, therefore reconsideration and allowance of this application is respectfully requested.

Respectfully submitted,



Blake E. Vande Garde
Attorney for Applicants
Registration No. 58,264

Customer No. 29494
Hammer & Associates, P.C.
3125 Springbank Lane
Suite G
Charlotte, NC 28226
Telephone: 704-927-0400
Facsimile: 704-927-0485
H:\2084\005\Amendment101209.doc